Philips: Tariff Refund Buoys Q2, But Underlying Margin Struggles and China Headwinds Persist
A solid quarter that hinges on a one-off tax refund; the real story is in the margin split and the company's pivot toward platform deals.
PHIA.AS · Earnings Call · 2026-07-28
A Quarter of Two Halves
Philips delivered exactly what it promised for the second quarter of 2026, but the numbers conceal a stark bifurcation. Tariff refund — a one-off benefit recognized in its entirety during the quarter — lifted the reported adjusted EBITA margin to 16.4%. Strip that out, and the underlying figure falls to 12.2%, a year-on-year decline of about 20 basis points. Roy Jakobs candidly framed it: “We delivered in line with our expectations in a dynamic external environment.” — Roy Jakobs, CEO · 2026-07-28 Indeed, the dynamic environment is precisely what makes the underlying margin decline noteworthy. Cost inflation, higher tariffs, and the expanding scope of China's centralized procurement are pressing on the company's profitability, even as it continues to extract productivity savings.
Excluding that benefit, our underlying margin was 12.2%.
The market has seen this before: across the sector, tariff refunds are being booked as a windfall, and Philips is riding that wave along with peers like tariff refund benefit</keyterm> names in the tape history. But the underlying economics tell a different story — one of sustained input-cost pressure and a mix shift that favors lower-margin volumes.
<h2>Margins Split: D&T Under Pressure</h2>
The most striking divergence is within the segments. Diagnosis & Treatment (D&T) saw its adjusted EBITA margin decline by roughly 420 basis points ex-tariff to 9.3%, a sharp reversal from the ~13.9% reported. CFO Charlotte Hanneman pointed to a confluence of factors: cost inflation hitting D&T harder than others, a full quarter of tariffs, negative currency effects, and a tough comparable from the prior year. She also flagged the persistent drag from China, particularly in Precision Diagnosis, where ultrasound and CT are most exposed to <keyword id="c7863ea19b">centralized procurement. The expansion of this policy across China has created timing delays and pricing pressure, a theme that dominated the Q&A. In contrast, Connected Care and Personal Health both expanded margins ex-tariff, with Personal Health surging to a 23% reported margin. This bifurcation is new — in prior quarters, D&T was the margin hero, driven by BlueSeal MR and Spectral CT. Now, the script has flipped.
Order Momentum and Platform Deals
Order intake declined 1% in Q2, but management insists this is a timing issue, not a demand issue. Large monitoring orders slipped into Q3, and Roy Jakobs explained: “In Diagnosis & Treatment, orders grew low single digit, following double-digit growth last year.” — Roy Jakobs, CEO · 2026-07-28 The underlying commercial momentum is, in their words, "resilient." A record equipment order book and the win of a 10-year cloud conversion with a leading U.S. health system underscore the shift toward enterprise-scale partnerships. What is changing is the conversion cycle: larger deals take longer to implement, and revenue recognition is now more SaaS-like. This is a structural evolution that may dampen near-term top-line growth even as the backlog builds. The company's own keyword trajectory highlights "order growth" and "good visibility" as top themes, but the market is watching whether these orders will convert to revenue at the pace implied by the full-year guidance.
China and the Selective Go-To-Market
China remains the key swing factor. The government's expansion of centralized procurement has now touched CT and ultrasound, forcing Philips to lean even harder on differentiated innovations. Roy reiterated the selective approach: “we have a very selective go-to-market approach in China” — Roy Jakobs, CEO · 2026-07-28, banking on helium-free MR and Spectral CT to escape price compression. But he also acknowledged that "we have been planning on a China that will remain more cautious." The offset is coming from North America and Europe, where order growth is double-digit in places, and from India, which appears as a new growth vector in the keyword movers. The ability to compensate for China is real, but the margin mix in those regions is less favorable. As the company reiterated its full-year guidance, the market is left to decide whether the Q4 margin acceleration — which Charlotte confidently predicts — will materialize without another one-off. History suggests caution: in prior calls, management was more bullish on China's recovery, but now the tone is more measured. “We are not relying on the China recovery in the rest of the year.” — Roy Jakobs, CEO · 2026-05-06
This quarter tells a tale of two Philips: a consumer powerhouse and a hospital systems business still digesting macro headwinds. The adjusted EBITA margin has become a battleground between the tariff refund's artificial boost and the underlying cost reality. Investors will be watching closely whether the productivity program can finally overcome the inflation tide in the second half.